Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.41 estudios en Endocrinología (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus Rochester, Minn. Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for the abnormal response to insulin. Likewise, we do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. We will measure muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates under both saline control (high overnight FFA) and after an overnight infusion of intravenous niacin (lower/normal FFA) to provide the first integrated examination of the interaction between FFA and muscle insulin action from the whole body to the cellular/molecular level. By identifying which steps in the insulin signaling pathway are most affected, we will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance. Hypothesis 1: Greater trafficking of plasma FFA into intramyocellular DG will impair proximal insulin signaling and reduce muscle glucose uptake. Hypothesis 2: Lowering FFA in UBO and T2DM by using an intravenous infusion of niacin will alter trafficking of plasma FFA into intramyocellular ceramides in a way that will improve insulin signaling and increase muscle glucose uptake. Hypothesis 3: Lowering FFA in UBO and T2DM by using an intravenous infusion of niacin will alter trafficking of plasma FFA into intramyocellular DG in a way that will improve insulin signaling and increase muscle glucose uptake. Correlation of Pancreatic Islet Morphology with Postprandial Glucose Tolerance in Subjects Undergoing Pancreatic Resection for Islet Cell Tumors Rochester, Minn. Determine the effect of endocrine pancreas morphology, turnover and dedifferentiation on glucose tolerance in humans. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla. The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients. A Study to Assess Maternal and Fetal Outcomes in Pregnancy with Type 1 Diabetes Mellitus and Controls Rochester, Minn. The purpose of this study is to retrospectively and prospectively compare maternal and fetal/newborn clinical outcomes in age-matched pregnant patients with T1D and healthy controls and to assess the relationship between glycemic variability and pregnancy outcomes in the current era. Obesity Treatment Outcomes in Liver Transplant Recipients Scottsdale/Phoenix, Ariz. The purpose of this study is to prospectively evaluate the safety and effectiveness of standard of care, individualized, comprehensive weight loss interventions in carefully selected patients with obesity undergoing liver transplant evaluation, including utilization of best lifestyle modifications and guidance to promote a healthy weight, possible medical therapy using FDA-approved weight loss medications and EBMTs with or without concomitant medical therapy. Neuroendocrine Tumors - Patient Reported Outcomes Rochester, Minn. The purpose of this study is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiveness and sequencing of therapy for patients with Neuroendocrine Tumors (NET). A Study of Immune Cell Abnormalities Found in Individual Patients who have Type 1 Diabetes and are Waiting for Pancreas or Pancreas/Kidney Transplant Surgery Rochester, Minn. The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on the waiting list for either a pancreas alone or a pancreas and kidney transplant. Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease Rochester, Minn. The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer. Glycemic Variability Assessment in Complex Diabetes During Hospitalization Rochester, Minn. The purpose of this study is to assess the glycemic variability in patients with complex diabetes admitted in the hospital using a glycemic sensor. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Solicite una consulta Ubicaciones, viajes y alojamientoInvestigación Nov. 02, 2019 Comparte en: FacebookTwitter EndocrinologíaSeccionesDescripción generalPruebas y procedimientosTrastornos que se tratanMédicosGrupos por especialidadUbicaciones, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencia en Mayo Clinic e historias de pacientesCostos y seguro médicoNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaDescripción generalPruebas y procedimientosTrastornos que se tratanMédicosGrupos por especialidadUbicaciones, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencia en Mayo Clinic e historias de pacientesCostos y seguro médicoNoticias de Mayo ClinicRemisiones ORG-20392484 Centros y departamentos médicos Endocrinología